bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.

bluebird bio, Inc. has filed supplemental disclosure with the SEC, amending its definitive proxy statement ahead of the annual meeting of stockholders scheduled for November 6, 2024. The company clarified who would bear the costs of soliciting proxies, stating that it would cover these expenses, primarily through mail and Internet, with additional outreach by employees and third-party firm Innisfree M&A Incorporated, for a fee not exceeding $30,000 plus expenses. Furthermore, bluebird bio addressed its non-compliance with Nasdaq's Minimum Bid Price Requirement, revealing that its stock closed below the $1.00 threshold for 32 consecutive business days. The company received a notice from Nasdaq on September 30, 2024, and has until March 31, 2025, to meet the requirement or face potential delisting. The company may seek an additional compliance period by transferring to the Nasdaq Capital Market, but there is no assurance of regaining compliance or maintaining other listing requirements.